Intercept v. Amneal: Obeticholic Acid Patent Dispute Ends in Consent Judgment
Intercept Pharmaceuticals and its European affiliate brought a four-patent infringement action against Amneal Pharmaceuticals and four related entities in the District of Delaware over obeticholic acid compositions and methods of use. The case closed after 880 days via a Consent Judgment entered in lead case 20-1105.
Four obeticholic acid patents, five Amneal entities, one agreed resolution
On 28 August 2020, Intercept Pharmaceuticals, Inc. and Intercept Pharma Europe Limited filed suit in the District of Delaware against Amneal Pharmaceuticals, Inc. and four affiliated entities — Amneal Pharmaceuticals of New York, LLC; Amneal Pharmaceuticals Company GmbH; Amneal Pharmaceuticals Pvt, Ltd.; and Amneal EU, Limited. The complaint asserted infringement of four US patents: US10174073B2, US9238673B2, US10052337B2, and US10047117B2, all directed to compositions of obeticholic acid and methods of its use.
The case was consolidated with or linked to lead case 20-1105 pending before Judge Maryellen Noreika. The recorded Basis of Termination is Consent Judgment; the docket order states that the case was closed per Consent Judgment entered in lead case 20-1105 at D.I. 309. A consent judgment is a binding, court-entered judgment on terms agreed by the parties, bringing the litigation to a formal close. The specific terms agreed between Intercept and Amneal are not disclosed in the available record.
The 880-day duration — spanning from August 2020 to January 2023 — is consistent with the typical lifecycle of multi-patent pharmaceutical disputes in Delaware, where discovery, claim construction, and any associated ANDA litigation proceedings can extend timelines significantly. What drove the parties toward an agreed resolution at this point in the proceedings, and what obligations or rights the consent judgment confers on either side, are not disclosed in the public record.
See Complete Case & Patent Analysis →Filing to Consent Judgment in 880 days
880 days from filing to consent judgment — longer than many ANDA-related patent disputes
US10174073B2 — Obeticholic acid compositions and methods of use
Any pharmaceutical company, formulator, or ANDA applicant developing obeticholic acid-based products or related bile acid therapeutics should treat all four asserted patents as active risk factors. Because the consent judgment in this case did not adjudicate validity or infringement, these patents remain unchallenged on the merits, and a freedom-to-operate analysis is essential before advancing an OCA product toward market.
Official order — verbatim text
The docket records closure via Consent Judgment entered in lead case 20-1105 at D.I. 309. This entry indicates the case was formally resolved through a court-entered agreed judgment rather than by adjudication on the merits. The specific terms binding the parties under that judgment are not reflected in the available docket record for this member case.
Consent judgment: what the agreed resolution means for both parties
What a consent judgment means in patent litigation
A consent judgment is a binding, court-entered judgment reflecting terms that the parties themselves have negotiated and agreed upon. Unlike a settlement agreement that merely dismisses claims, a consent judgment carries the full force of a court order, meaning either party may return to court to enforce its terms. The docket records this as entered in lead case 20-1105 at D.I. 309. The specific agreed terms are not disclosed in the available record.
Court-entered, binding judgmentIntercept secures a court-entered judgment on agreed terms
For Intercept Pharmaceuticals and Intercept Pharma Europe Limited, the consent judgment provides a formally enforceable resolution across all four asserted patents and against all five Amneal entities. The court's entry of the judgment means Intercept retains the ability to seek judicial enforcement of the agreed terms if necessary. What specific rights or restrictions flow to Intercept from the agreed terms is not disclosed in the public record.
Enforceable across all five entitiesAmneal entities bound by court-entered consent judgment
All five Amneal entities — spanning the US, New York, Switzerland, India, and EU — are parties to the consent judgment and are bound by its terms as entered by the court. This global entity coverage suggests a coordinated resolution across Amneal's manufacturing and distribution structure. The obligations or rights conferred on Amneal under the consent judgment are not disclosed in the available public record.
Five Amneal entities coveredObeticholic acid IP landscape: a precedent for generic entry timing
Consent judgments in pharmaceutical patent cases — particularly those involving ANDA-related filings — can structure the timing of generic market entry without full adjudication of validity or infringement. Other generic pharmaceutical companies monitoring obeticholic acid patent coverage should note that the four asserted patents remain in force and that the terms of any market-entry arrangement between these parties are not publicly available.
Generic entry terms undisclosedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Intercept Pharmaceuticals, Inc. | Company | Pharmaceutical company — holder of US10174073B2 and three further obeticholic acid patentsSearch in Eureka ↗ |
| Co-Plaintiff | Intercept Pharma Europe Limited | Company | Search in Eureka ↗ |
| Defendant | Amneal Pharmaceuticals, Inc. | Company | Generic pharmaceutical manufacturer and affiliated global entities contesting obeticholic acid patent claimsSearch in Eureka ↗ |
| Co-Defendant | Amneal Pharmaceuticals of New York, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Amneal Pharmaceuticals Company GmbH | Company | Search in Eureka ↗ |
| Co-Defendant | Amneal Pharmaceuticals Pvt, Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Amneal EU, Limited | Individual | Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Intercept Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jeremy A. Tigan | Attorney | Counsel for Intercept Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Mary K. Swears | Attorney | Counsel for Intercept Pharmaceuticals, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Intercept Pharmaceuticals, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the obeticholic acid and bile acid therapeutic space
Forward-looking patent and innovation intelligence derived from Intercept Pharmaceuticals' OCA portfolio and Amneal's generic pharmaceutical IP posture.
Intercept's layered OCA patent filings signal ongoing exclusivity strategy
Intercept's assertion of four distinct patents — spanning compositions and methods of use with application numbers ranging across US13, US14, and US15 series — suggests a continuation-heavy prosecution strategy designed to extend effective exclusivity. Monitoring Intercept's downstream continuation and divisional filings in this family is advisable for any team working on bile acid therapeutics.
Continuation filing activityBile acid derivative therapeutics: filing trends around FXR agonists
Obeticholic acid is an FXR agonist, and the broader FXR agonist therapeutic space has seen sustained patent filing activity from multiple pharmaceutical companies. Mapping the density of claims around OCA analogues, formulation types, and dosage methods can reveal white space for next-generation bile acid therapeutics that design around Intercept's existing claim scope.
FXR agonist filing trendsAmneal's generic pharma IP position in specialty therapeutic areas
Amneal Pharmaceuticals' multi-jurisdictional entity structure — US, EU, India, Switzerland — reflects a global manufacturing and filing footprint. Analysing Amneal's own patent activity in specialty pharmaceutical formulations and process chemistry can indicate where they may be building defensive IP to support future generic or 505(b)(2) product strategies beyond obeticholic acid.
Amneal formulation IP activityAdjacent OCA claim space: formulation delivery and combination therapy
The four asserted patents focus on OCA compositions and methods of use; adjacent areas including novel drug delivery mechanisms, combination therapies with other bile acid modulators, and paediatric formulations may represent underprotected technical territory. R&D teams should use patent landscaping to assess claim density in these adjacent domains before investing in new development programmes.
Formulation white spaceSimilar pharmaceutical patent infringement cases in Delaware District Court
Explore related ANDA-adjacent patent infringement cases involving pharmaceutical compositions and bile acid therapeutics filed in the District of Delaware.
What this case signals for the pharmaceutical patent IP landscape
Four obeticholic acid patents, five defendants, and a consent judgment in Delaware — key signals for pharma IP strategy.
Multi-entity defendants in ANDA-style disputes require coordinated IP strategy
Amneal's five-entity structure — spanning US, EU, India, and Switzerland — reflects the global manufacturing and distribution footprint of major generic challengers. Patent holders facing similar defendants should ensure their infringement claims and any resulting consent judgments cover all relevant affiliated entities to prevent enforcement gaps.
Consent judgments preserve enforcement rights that pure dismissals do not
Unlike a stipulated dismissal, a consent judgment entered by the court gives the patent holder an ongoing enforcement mechanism. For pharmaceutical patentees, this distinction matters when managing multi-year exclusivity windows and potential future generic re-entry attempts. The court's retained jurisdiction to enforce the judgment is a meaningful structural advantage.
Intercept v Amneal — key questions answered
The case closed on 25 January 2023 via a Consent Judgment entered in lead case 20-1105 (D.I. 309) before Judge Maryellen Noreika in the District of Delaware. The recorded Basis of Termination is Consent Judgment. The specific terms of the agreed judgment are not disclosed in the available public record.
Intercept asserted four US patents: US10174073B2, US9238673B2, US10052337B2, and US10047117B2. All four relate to compositions of obeticholic acid and methods of its preparation and use. None of the patents was adjudicated on the merits in this proceeding.
A consent judgment is a binding, court-entered judgment reflecting terms agreed by the parties. Unlike a stipulated dismissal, a consent judgment carries the full force of a judicial order, allowing either party to return to court for enforcement. It formally resolves the litigation without requiring a trial or merits adjudication.
The plaintiff named Amneal Pharmaceuticals, Inc. alongside four affiliated entities: Amneal Pharmaceuticals of New York, LLC; Amneal Pharmaceuticals Company GmbH; Amneal Pharmaceuticals Pvt, Ltd.; and Amneal EU, Limited. This multi-entity naming is consistent with pharmaceutical patent suits targeting a generic manufacturer's full global manufacturing and distribution structure to ensure comprehensive coverage of any infringing activities.
No. A consent judgment entered without a merits adjudication does not constitute a ruling on patent validity or infringement. The four asserted patents — US10174073B2, US9238673B2, US10052337B2, and US10047117B2 — remain in force and have not been declared valid, invalid, or non-infringed as a result of this proceeding.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.